Description
Nano RSV Test Shelf-life Extension (4-25-2025)
Unit: 1 Box (25 Tests)
Regulatory Status: CLIA Waived (Nasal Swab) / Moderately Complex (Nasal Wash / Nasal Aspirate) / Professional Use Only
Contents:25 Test devices in sealed aluminum foil pouch with desiccant, 25 Reagent tubes prefilled with extraction buffer (350 µL) and dropper tips, 25 Sample collection swabs (Anterior Nasal), 1 Positive control swab (noninfectious RSV antigen), 1 Negative control swab (noninfectious nasal clinical matrix), 1 Instructions for Use, 1 Quick Reference Instruction
Determinations: Qualitative Respiratory Syncytial Virus (RSV)
Storage Requirements: 59° – 86° F
Processing Time: 15 Minutes
The Nano-Check™ RSV Test is a rapid immunochromatographic assay for the qualitative detection of respiratory syncytial virus (RSV) nucleoprotein antigen in anterior nasal swab specimens from patients with signs and symptoms of respiratory infections. This test is intended for in vitro diagnostic use to aid in the diagnosis of RSV infections in infants and
pediatric patients aged 6 months to 6 years old, and adults over 60 years of age.
The Nano-Check™ RSV Test provides a simple, rapid method for the diagnosis of RSV using anterior nasal swab (ANS) specimens. Its userfriendly format and rapid results allow for quick diagnosis and aid in treatment and hospitalization decisions
About RSV
The RSV virus is an enveloped, non-segmented, negative-sense RNA virus classified in the subfamily Pneumovirinae of the Paramyxoviridae family. Virus replication begins in the nasopharynx, then replicates principally in the superficial layer of the respiratory epithelium and then spreads downward into the lower respiratory tract through the inhalation of secretions. This causes inflammation of the bronchioles resulting in wheezing, difficulty breathing, and sometimes respiratory failure.
Respiratory syncytial virus is spread easily through inhalation of virus-laden aerosolized particles (produced by normal breathing, speaking, singing, coughing, or sneezing ), direct contact with infected individuals, or contact with contaminated objects. The virus can linger on surfaces for up to eight hours and can be contagious for up to 8 days. Infections normally occur in the US between November and April. Infection can occur at all ages, but can be more critical in premature infants; children with chronic lung disease, congenital heart disease, or immune system deficiencies; and adults over the age of 65.
The typical RSV infection causes mild, cold-like symptoms in adults and healthy school-aged children. Symptoms tend to appear 4-6 days after exposure and include a coughing, sneezing, stuffy and/or runny nose, fever, and a decreased appetite. These symptoms normally diminish in 7 to 14 days, but the cough may linger for weeks. Complications with RSV that can occur in higher risk patients include croup, ear infections, and pneumonia. There is no treatment option for RSV viral infections. Mild infections resolve on their own. However, supportive care can be used in the form of bronchiodilators (to keep airways open), humidifiers, and over-the-counter medications to relieve symptoms.
For more severe cases and high-risk patients, doctors may prescribe an antiviral medication. Antiviral medications can be used to effectively reduce the intensity and duration of symptoms, but they cannot treat or prevent infection of RSV. These medications work best if the patient begins taking them at early on-set of symptoms. The QuickVue RSV Test combines testing, diagnosis, and symptom management all in the same doctor’s visit, which could reduce the potential for serious complications.
